COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
A Paradigm Shift to Prevent and Treat Alzheimer's Disease - 1st Edition - ISBN: 9780128122594, 9780128122792

A Paradigm Shift to Prevent and Treat Alzheimer's Disease

1st Edition

From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols

Authors: Howard Friel Sally Frautschy
Paperback ISBN: 9780128122594
eBook ISBN: 9780128122792
Imprint: Academic Press
Published Date: 19th July 2017
Page Count: 290
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


A Paradigm Shift to Prevent and Treat Alzheimer’s Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols is the first book to systematically exhibit the powerful pleiotropic pharmacological effects on Alzheimer’s disease of plant-based compounds from ancient foods that humans have been consuming safely with substantial health benefits for thousands of years.

These plant-based compounds include curcuminoids from turmeric, resveratrol from red wine and grape seed extract from other grape products, epigallocatechin-gallate (EGCG) from green tea, and oleocanthal and oleuropein from olive oil, in addition to a special extract, EGb 761, from the leaves of Ginkgo biloba, the oldest living species of tree on earth.

This book also presents a new analytical framework that convincingly favors a multi-targeting ("pleiotropic") approach to the prevention and treatment of complex chronic diseases, in contrast to the mono-targeting of the pharmaceutical model.

A Paradigm Shift to Prevent and Treat Alzheimer’s Disease is a unique and exciting resource for pharmaceutical scientists, pharmacologists, neurologists, general practitioners, research scientists in various medical and life sciences, healthcare professionals in clinical and executive positions, conventional medical schools, schools of naturopathic medicine, healthcare and medical journalists, executives in both national public healthcare systems and private insurers, and informed general readers.

Key Features

  • Presents carefully compiled evidence supporting the need to shift from pharmaceutical-based mono-targeting to plant polyphenol-based pleiotropic targeting for the prevention and treatment of Alzheimer’s disease
  • Includes valuable tables that aggregate pleiotropic pharmacological effects of the plant polyphenols on Alzheimer’s disease-related pathogenic hallmarks
  • Highlights regulatory aspects and discusses the challenges and potential solutions with respect to bioavailability of certain plant polyphenols


Researchers in Pharmacology and Pharmaceutical Science, Neurology and Neuroscience; Practicing Neurologists; Clinical Researchers; Family Practice Physicians, Medical Students; Medical and Healthcare Journalists

Table of Contents

Part I
1. Mono-targeting vs. Multi-targeting
2. The Pleiotropic Pharmacology of Plant Polyphenols

Part II
3. Primary Prevention of of Alzheimer's Disease
4. Secondary Prevention of Alzheimer's Disease
5. Treatment Mechanisms in Mild to Moderate Alzheimer's Disease
6. Pleiotopic Theory

Part III
7. Dose Adherence and Intent-to-Treat


No. of pages:
© Academic Press 2017
19th July 2017
Academic Press
Paperback ISBN:
eBook ISBN:

About the Authors

Howard Friel

Howard Friel is a book author who writes about foreign policy, public international law, international humanitarian law, human rights, civil liberties, and science-related issues. Friel has written four books to date: Chomsky and Dershowitz: On Endless War and the End of Civil Liberties (Olive Branch Press, 2014); The Lomborg Deception: Setting the Record Straight about Global Warming (Yale University Press, 2010); Israel-Palestine on Record: How the New York Times Misreports Conflict in the Middle East (with Richard Falk) (Verso, 2007), and The Record of the Paper: How the New York Times Misreports U.S. Foreign Policy (with Richard Falk) (Verso, 2004).

Affiliations and Expertise

Book author who writes about foreign policy, public international law, international humanitarian law, and science-related issues, USA

Sally Frautschy

Sally Frautschy is Professor of Neurology at the David Geffen School of Medicine at the University of California at Los Angeles. The laboratory that Frautschy founded with Greg Cole at UCLA conducts research to better understand the cellular, biochemical, and genetic pathways that disrupt cognition in Alzheimer's disease. Dr. Frautschy has coordinated her lab’s research with the NIH National Consortium Clinical Trials and the UCLA Alzheimer Center to accelerate effective prevention and treatment methods for Alzheimer’s disease.

Affiliations and Expertise

Professor-in-Residence of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, David Geffen School of Medicine, University of California, Los Angeles, VA Greater Los Angeles Healthcare System, West Los Angeles Medical Center


"This is a wonderful book for people who are looking for ways by which we will overcome Alzheimer's disease, the most common dementing disorder affecting middle-aged and old people. 

On understanding of the pathophysiology of Alzheimer's disease, the authors clearly explain and discuss multiple ("pleiotropic") effects of plant polyphenols on Alzheimer's disease from multiple viewpoints, including epidemiology, sequential events in the brain that lead to disease initiation and progression, and current status of human trials with polyphenols.

Plant polyphenols that have effects on the multiple pathomechanisms of Alzheimer's disease are expected to prevent or delay the disease onset and progression safely, effectively, and inexpensively. We need further studies to establish this." --Masahito Yamada is Professor and Chair, Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences

"This timely book by Howard Friel and Sally Frautschy provides an in-depth discussion of an approach to the treatment of Alzheimer's disease (AD) that is very distinct from the one that has been taken by the pharmaceutical industry. Since none of the drug candidates promoted by the pharmaceutical industry for AD treatment over the past 20 years have succeeded in the clinic, alternative approaches are desperately needed. This book should be of great interest to clinicians/health care workers and research scientists as well as the informed layperson. For clinicians/health care workers, the book provides a potential road map for the treatment of patients ranging from those with only very mild cognitive problems to cases of more severe memory impairment. Since there are currently no effective treatments for AD, this road map could give new hope to patients and their care providers. For the research scientist outside the AD field, the book provides an excellent, thoroughly referenced introduction to AD. And, for the AD scientist, the book suggests new avenues of research. Finally, for the informed lay person, the book identifies safe approaches for the prevention of this devastating disease. Thus, this volume makes a significant and much needed contribution to the AD field and should be highly appreciated by many." --Pamela Maher is a Senior Staff Scientist in Cellular Neurobiology at the Salk Institute for Biological Studies in La Jolla, California 

"This book from Friel and Frautschy rigorously supports the thesis that multi-mechanistic, non-toxic, polyphenolic compounds found in the ancient foods of tea, turmeric, olive oil, and red wine are superior to mono-targeting pharmaceuticals for the prevention and treatment of numerous chronic diseases in humans, in this case Alzheimer’s disease." --Navindra P. Seeram, Associate Professor in the Department of Biomedical and Pharmaceutical Sciences, Botanical Research Laboratory, College of Pharmacy, University of Rhode Island.

Ratings and Reviews